These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 22499288

  • 21. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 22. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 14; 23(2):443-57. PubMed ID: 17288698
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC.
    J Hum Hypertens; 2004 Jun 14; 18(6):367-73. PubMed ID: 15029217
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
    Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlöf B, Wachtell K.
    Blood Press; 2012 Feb 14; 21(1):6-11. PubMed ID: 22070095
    [Abstract] [Full Text] [Related]

  • 32. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB.
    Hypertension; 2005 Jan 14; 45(1):46-52. PubMed ID: 15583076
    [Abstract] [Full Text] [Related]

  • 33. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K.
    Circulation; 2004 Sep 14; 110(11):1456-62. PubMed ID: 15326072
    [Abstract] [Full Text] [Related]

  • 34. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K.
    Circulation; 2007 Aug 14; 116(7):700-5. PubMed ID: 17664372
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN, Devereux RB, Okin PM.
    J Electrocardiol; 2014 Aug 14; 47(5):630-5. PubMed ID: 25052475
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB.
    Circulation; 2005 Apr 19; 111(15):1924-31. PubMed ID: 15837945
    [Abstract] [Full Text] [Related]

  • 39. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB.
    J Hypertens; 2008 Jun 19; 26(6):1244-9. PubMed ID: 18475164
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.